EIKNEikon Therapeutics, Inc.
Next earnings ≈ Aug 3, 2026 · est. from filing cadence
Last earnings -0.1% on 2026-05-11
$10.58
▼ -5.70%$10.58▼ -29.47%
over 1Y
L $8.36H $16.26
Our buy Our hold Our sell Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today
-5.7%
1W
-12.1%
1M
+26.6%
3M
+17.6%
YTD
-29.5%
1Y
-29.5%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Mixed signals in the latest filings.
This call stands until the filings change it — the engine re-rates on new 10-K/10-Q/8-K facts, never on price moves. Hit Watch above to follow EIKN (Pro alerts fire the moment a rating flips), or catch every change in Saturday’s Flip Side. How to read a call
Eikon Therapeutics, Inc. shows limited reported revenue.
On these fundamentals, EIKN screens as SELL on the SEC figures.
Is EIKN a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread~60d expiry
- Long put 10.5 @ ~1.45 est
- Short put 9.5 @ ~0.95 est
debit $50max +$50max −$50BE 10.00
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Key statistics
Valuation
Enterprise value$599M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timelineSEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-10
- 8-K Reg FD disclosure2026-06-01
- 8-K Earnings results2026-05-11
- 10-Q Quarterly report2026-05-11
- 8-K Earnings results2026-03-30
- 10-K Annual report2026-03-30
- 8-K Charter / bylaws change2026-02-06
- S-1/A Securities registration2026-01-28
- S-1 Securities registration2026-01-09
Recent filings
all on EDGAR ↗3Period ending 2026-06-152026-06-15open ↗8-KPeriod ending 2026-06-052026-06-10open ↗8-KPeriod ending 2026-05-302026-06-01open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-13open ↗10-QPeriod ending 2026-03-312026-05-11open ↗8-KPeriod ending 2026-05-112026-05-11open ↗SCHEDULE 13GFiling2026-05-06open ↗SCHEDULE 13GFiling2026-04-29open ↗8-KPeriod ending 2026-03-302026-03-30open ↗10-KPeriod ending 2025-12-312026-03-30open ↗4Period ending 2026-03-022026-03-04open ↗
Frequently asked
- Is Eikon Therapeutics, Inc. (EIKN) a buy?
- EIKN currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
Sources: SEC EDGAR (CIK 0001861123, latest 10-Q filed 2026-05-11) · EODHD · as of 7/11/2026, 9:53:54 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 11, 2026, 5:53 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.